A pancreatic cancer mouse model with human immunity
N. Miyamura, K. Suzuki, R. A. Friedman, A. Floratos, Y. Kunisada, K. Masuda, A. M. Lowy, M. Tsuji, K. N. Sugahara
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a tumor immune microenvironment (TIME) that promotes resistance to immunotherapy. A preclinical model system that facilitates studies of the TIME and its impact on the responsiveness of human PDAC to immunotherapies remains an unmet need. We report a novel mouse model, which develops metastatic human PDAC that becomes infiltrated by human immune cells recapitulating the TIME of human PDAC. The model may serve as a versatile platform to study the nature of human PDAC TIME and its response to various treatments.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma
K. E. Baxter, C. Tanese de Souza, … R. C. Auer·bioRxiv·Mar 17, 2020
- Clinically relevant orthotopic pancreatic cancer models for adoptive T cell therapy
N. K. Horvat, I. Karpovsky, … G. B. Lesinski·bioRxiv·Sep 7, 2023
- Immune Selection Pressure Contributes to Pancreatic Cancer Immune Evasion
R. Ajina, A. Zuo, … L. M. Weiner·bioRxiv·Jun 15, 2020
- TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma
Anna D. Louie, Kelsey E. Huntington, … Wafik S. El‐Deiry·American Journal of Cancer ResearchPeer-reviewed·Jan 1, 2025
- Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
B. C. Selvanesan, K. Meena, … C. Gravekamp·bioRxiv·Jun 2, 2020
- Multi-omics and functional analysis of a bioengineered vascularized pancreatic cancer model reveal an immunosuppressive and therapy-resistant niche
Giulio Giustarini, Kok Siong Ang, … Giulia Adriani·bioRxiv·Mar 9, 2026